Research programme: beta-lactamase inhibitors - Mirati Therapeutics

Drug Profile

Research programme: beta-lactamase inhibitors - Mirati Therapeutics

Alternative Names: MG 2121; MG 2204; MG 2394; MG 2907; MG 2913; MG 3394; MG 84760; MG 96077

Latest Information Update: 05 Jul 2013

Price : $50

At a glance

  • Originator MethylGene
  • Class Small molecules
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • Available For Licensing Yes

Highest Development Phases

  • Suspended Bacterial infections

Most Recent Events

  • 28 Jun 2013 Mirati Therapeutics is now the parent company of MethylGene
  • 02 Sep 2010 Preclinical development is ongoing in Canada
  • 14 Sep 2009 Preclinical trials in Bacterial infections in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top